Showing 1 to 3 of 3 results


FDA Approves Novel Non-Opioid Painkiller Journavx
The FDA approved Vertex's non-opioid painkiller, Journavx, for moderate-to-severe acute pain, offering an addiction-free alternative impacting 80 million annual U.S. patients and potentially generating over $1 billion in annual sales.
FDA Approves Novel Non-Opioid Painkiller Journavx
The FDA approved Vertex's non-opioid painkiller, Journavx, for moderate-to-severe acute pain, offering an addiction-free alternative impacting 80 million annual U.S. patients and potentially generating over $1 billion in annual sales.
Progress
44% Bias Score


FDA Approves First New Non-Opioid Painkiller in Over Two Decades
The FDA approved suzetrigina, a new non-opioid painkiller, offering an alternative to opioids for acute pain; studies show comparable effectiveness to Vicodin for post-surgical pain, but further research is needed for chronic pain.
FDA Approves First New Non-Opioid Painkiller in Over Two Decades
The FDA approved suzetrigina, a new non-opioid painkiller, offering an alternative to opioids for acute pain; studies show comparable effectiveness to Vicodin for post-surgical pain, but further research is needed for chronic pain.
Progress
48% Bias Score

FDA Approves First New Non-Opioid Painkiller in Over 20 Years
The FDA approved Journavx (suzetrigine), a non-opioid painkiller, to treat moderate to severe acute pain in adults; clinical trials showed it reduced pain by 50% in 48 hours and is as effective as hydrocodone, but non-addictive.

FDA Approves First New Non-Opioid Painkiller in Over 20 Years
The FDA approved Journavx (suzetrigine), a non-opioid painkiller, to treat moderate to severe acute pain in adults; clinical trials showed it reduced pain by 50% in 48 hours and is as effective as hydrocodone, but non-addictive.
Progress
48% Bias Score
Showing 1 to 3 of 3 results